Nyxoah S.A. (NYXH)

Executive Summary / Key Takeaways

• The US Launch Inflection Is Real But Incomplete: Nyxoah's FDA approval in August 2024 unlocked a $10 billion US market, driving 122% revenue growth to €10 million and generating genuine physician enthusiasm. However, with €3.65 million in US sales over the initial launch period, the company has proven it can enter the market, though it faces a dominant incumbent.

• Technology Differentiation Creates a Narrow Moat: Genio's bilateral stimulation , single-incision procedure, and battery-free design offer tangible advantages—full-body MRI compatibility and no re-surgery for battery replacement—that resonate with surgeons and patients. This provides a credible basis for gaining share from Inspire Medical Systems (INSP) and its significant US market dominance, but the moat is narrow: established reimbursement and surgeon relationships remain formidable barriers.

• Cash Runway Is the Overriding Constraint: With €48 million in cash and a quarterly burn rate approaching €20 million, Nyxoah faces substantial doubt about its ability to continue as a going concern. The company requires significant additional capital to reach profitability at €150 million revenue, implying potential dilution or debt ahead.

• Patent Litigation Threatens the Critical Launch Window: A patent lawsuit from the primary incumbent creates risk beyond legal costs. With a trial not expected until 2027, the uncertainty could slow surgeon adoption and VAC approvals during Nyxoah's growth phase, potentially impacting the 25% sequential growth management targets for early 2026.

• GLP-1 Drugs Are a Net Positive But Misunderstood: While GLP-1s could treat mild OSA, they may expand Nyxoah's eligible patient pool by bringing high-BMI patients down to Genio's effective range. This reframes a perceived threat as a tailwind, potentially increasing the US target market by 15-20% over time.

Setting the Scene: A David vs. Goliath Battle for the Airway

Nyxoah SA, headquartered in Mont-Saint-Guibert, has spent fifteen years developing a solution for moderate to severe obstructive sleep apnea (OSA). The company's sole commercial product, the Genio system, represents a technological leap in hypoglossal neurostimulation (HGNS)—a surgically implanted device that stimulates tongue muscles to keep airways open during sleep. Approximately 425 million people globally suffer from moderate to severe OSA, and in the United States alone, an estimated 510,000 patients annually represent a $10 billion addressable market. Yet the HGNS segment has been concentrated, with Inspire Medical Systems controlling the vast majority of the US market through its first-mover advantage.

The industry's core challenge is CPAP non-compliance. Studies show 29-83% of patients cannot tolerate continuous positive airway pressure therapy. This creates a large, underserved population seeking surgical alternatives. However, the barrier to entry is high: FDA approval requires multi-year pivotal trials; reimbursement demands securing coverage from hundreds of insurers; and surgeon adoption requires extensive training. Nyxoah has cleared these hurdles, obtaining FDA approval in 2024 after its DREAM pivotal trial met primary endpoints. The focus now shifts to whether Nyxoah can scale fast enough to survive its cash consumption.

Technology, Products, and Strategic Differentiation: Why Genio Is Not Just Another Implant

Genio's architecture challenges incumbent design. While other systems require multiple incisions—one for a chest-worn battery pack and another for the neurostimulator—Genio achieves bilateral stimulation through a single incision with a leadless, externally-powered device. This impacts adoption and economics in three ways.

First, surgeon efficiency: A single-incision procedure reduces operative time, enabling centers to treat more patients. Surgeons cite this as a key differentiator, particularly in high-volume accounts that represent the majority of total HGNS procedures. In an environment where hospital margins are under pressure, procedure efficiency translates to institutional adoption.

Second, patient value proposition: The battery-free design eliminates the need for re-surgery every 8-10 years when batteries deplete. Combined with full-body MRI compatibility at both 1.5T and 3T, Genio appeals to younger patients who view the implant as a long-term solution. Management reports an average patient age in the early 50s, indicating selection of patients who will live with the device for decades.

Third, clinical breadth: Bilateral stimulation treats both sides of the tongue simultaneously, which clinical data suggests is effective for complex airway obstruction, including complete concentric collapse (CCC) . While Genio's US approval doesn't yet include CCC, the European CE-Mark does, and the ongoing ACCCESS trial could enable a US label expansion in early 2027. This would open a patient segment currently denied neurostimulation therapy, potentially expanding the addressable market by over a third.

The Genio 2.10 system adds Bluetooth connectivity, but the margin story lies in Genio 2.2, expected in 2027. This next-generation device aims to reduce disposable patch costs, driving gross margins from the current 63% toward a 70%+ target. At €150 million revenue, Nyxoah expects positive Adjusted EBITDA. Every percentage point of margin improvement accelerates that path.

Financial Performance: Growth at the Cost of Survival

The 2025 results show revenue surged 122% to €10 million, driven by the US launch's €3.65 million contribution. Q4 alone generated €5.6 million net revenue, with the US contributing €3.5 million. This demonstrates demand and validates the value proposition.

However, the cost of this growth is high. Operating loss widened to €83.5 million from €58.8 million in 2024, as SG&A expenses increased to €48.3 million to build the US commercial organization. R&D increased to €43 million, reflecting investment in the ACCCESS trial and next-generation products. Net cash used in operations reached €69 million, up from €49.2 million in 2024.

The company is front-loading commercial infrastructure—hiring sales reps, training surgeons, and securing approvals—before revenue can scale. The strategy assumes early investments create a durable commercial footprint.

Gross margin at 63% trails the 85% seen at Inspire Medical Systems and the 61% at ResMed (RMD). The gap reflects Nyxoah's current scale, spreading fixed manufacturing overhead over a smaller number of annual implants. Guidance for 70%+ margins in 2027 hinges on volume growth and cost reductions from Genio 2.2. If Nyxoah cannot scale volume significantly by 2027, margins may remain under pressure.

The balance sheet shows that as of December 31, 2025, Nyxoah held €48 million in cash and financial assets. Recent financing provides some breathing room, but a quarterly burn rate of approximately €20 million means the runway is limited. Nyxoah likely needs to raise at least €110 million more to reach the €150 million revenue profitability threshold.

Competitive Context: Chipping Away at a Fortress

Inspire Medical Systems is the incumbent with a moat built over a decade. With nearly $1 billion in annual revenue and substantial cash reserves, it has the resources to invest heavily in surgeon training and marketing. Its extensive surgeon network and established reimbursement create switching costs for new entrants.

Where Nyxoah wins: In evaluations, surgeons cite Genio's single-incision technique and bilateral stimulation as advantages for complex cases. Patient preference for a battery-free, MRI-compatible device is a factor. In European markets where both are available, Nyxoah has carved out share, with Germany achieving profitability. This suggests the technology can compete effectively when reimbursement is established.

Where Nyxoah loses: Inspire's closed-loop system , which adjusts stimulation based on breathing patterns, offers a data-driven approach. Furthermore, a patent lawsuit alleging Genio infringes intellectual property creates uncertainty. Even if Nyxoah prevails, the litigation will require resources and management attention during a critical growth window.

LivaNova (LIVN) and its aura6000 system, expected to launch in the US in 2027, adds another potential competitor. LivaNova's neuromodulation expertise and diversified balance sheet make it a notable player in the space.

Indirect competition from GLP-1 drugs like Wegovy from Novo Nordisk (NVO) is a factor. While these drugs could reduce OSA severity, they may also expand the eligible HGNS population by bringing high-BMI patients into the treatable range. Data showing BMI reductions means more patients could qualify for Genio, potentially transforming a perceived headwind into a tailwind.

Outlook, Guidance, and Execution Risk: The 25% Promise

Management's guidance for 25% sequential US revenue growth in the first half of 2026 assumes continued surgeon training and growing adoption. Q4 2025's €3.5 million US revenue implies approximately 140 implants. To grow 25% sequentially, Nyxoah needs to increase this volume steadily. With an expanding sales force, this requires each rep to generate consistent implant volume—a goal that depends on the pace of hospital approvals.

The sales force expansion plan signals confidence. Management expects initial reps to generate significant annual revenue, with full productivity increasing over time. This trajectory is intended to put the company on track for higher total revenue, though it remains below the €150 million profitability threshold in the near term.

The ACCCESS study, with data expected in late 2026, is a major catalyst. If results show Genio is effective for CCC patients, Nyxoah could seek a US label expansion in 2027. This would open a patient segment currently excluded from HGNS therapy. The risk remains that data could be inconclusive or require further study.

Manufacturing scale-up is also critical. A new facility in Belgium, expected to be operational in 2027, aims to reduce reliance on third-party suppliers and improve margins. Until then, the company depends on external manufacturing, which carries supply chain considerations if demand increases rapidly.

Risks and Asymmetries: What Can Break the Thesis

Going Concern Considerations: The explicit mention of substantial doubt regarding the ability to continue as a going concern for at least twelve months is a significant risk factor. This can influence how partners and surgeons view the company's long-term stability. The projected capital need is a constraint; securing this funding is essential for the company's trajectory.

Reimbursement and Execution: While current reimbursement levels are favorable, commercial payers could change policies. If insurers require more data or impose hurdles, growth targets may be harder to reach. Furthermore, the thesis rests on scaling from hundreds to thousands of annual implants. This requires execution across manufacturing, sales, and training. Any delays in these areas could extend cash burn.

Patent Litigation: The ongoing legal dispute with the primary incumbent involves significant stakes. Legal costs are a burden, and the potential for an injunction or unfavorable ruling represents a risk to US sales during the trial period.

Valuation Context

With a market cap of approximately $155 million, Nyxoah trades at a high multiple of trailing sales, which assumes significant growth from the US launch. Balance sheet metrics show a current ratio of 1.25, providing a limited cushion.

Peer comparisons show that established players like Inspire and ResMed trade at different valuation levels based on their profitability and market position. Nyxoah's valuation is tied to its ability to achieve high revenue growth and reach profitability in the coming years. The stock currently reflects a high-growth expectation, making equity value sensitive to the success of future capital raises.

Conclusion: A High-Reward Call Option on Execution Excellence

Nyxoah's investment thesis is centered on its transition from development to commercial scale. The company has achieved FDA approval and demonstrated product differentiation. The Genio system's bilateral stimulation and single-incision approach have gained early US traction.

However, this opportunity is paired with capital constraints. The company must manage a significant quarterly burn while scaling its organization and navigating litigation. The 25% sequential growth target is a key milestone on the path toward the €150 million revenue needed for profitability.

The competitive landscape is led by a well-capitalized incumbent. Nyxoah aims to gain ground through its technology and execution. The patent lawsuit remains a variable that could impact the growth window.

For investors, the situation represents a high-stakes scenario tied to management's ability to scale revenue, secure financing, and manage legal and manufacturing hurdles. The potential for significant returns exists if Nyxoah captures a meaningful portion of the HGNS market, while the downside is linked to the risks of its current capital position. Key variables to monitor include US implant volumes, the rate of cash burn, and legal developments.